Fibrocell to Present at Phacilitate Cell and Gene Therapy World 2018
January 24, 2018 08:00 ET
|
Fibrocell Science Inc
EXTON, Pa., Jan. 24, 2018 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ:FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue...
Fibrocell Announces Closing of $10.5 Million Underwritten Public Offering
December 11, 2017 16:01 ET
|
Fibrocell Science Inc
EXTON, Pa., Dec. 11, 2017 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ:FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue...
Fibrocell Announces Pricing of $10.5 Million Underwritten Public Offering
December 07, 2017 07:00 ET
|
Fibrocell Science Inc
EXTON, Pa., Dec. 07, 2017 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ:FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue...
Fibrocell Reports Third Quarter 2017 Financial Results and Recent Highlights
November 13, 2017 08:00 ET
|
Fibrocell Science Inc
EXTON, Pa., Nov. 13, 2017 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ:FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue...
Fibrocell to Host Conference Call and Webcast on Monday, November 13, 2017 to Discuss Third Quarter 2017 Financial Results and Recent Operational Highlights
November 06, 2017 08:00 ET
|
Fibrocell Science Inc
EXTON, Pa., Nov. 06, 2017 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ:FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue...
Fibrocell to Present at 2017 Cell & Gene Meeting on the Mesa
October 02, 2017 16:30 ET
|
Fibrocell Science, Inc.
EXTON, Pa., Oct. 02, 2017 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc., (NASDAQ:FCSC) today announced that John Maslowski, President and Chief Executive Officer of Fibrocell, will present at 3:00 pm...
Fibrocell Reports Interim Results of Phase 1/2 Clinical Trial of FCX-007 Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa
September 26, 2017 08:00 ET
|
Fibrocell Science, Inc.
– FCX-007 well-tolerated through 12 weeks post-administration with encouraging safety and positive early trends noted in wound healing and pharmacology signals – – Data Safety Monitoring Board...
Fibrocell to Present at Rodman & Renshaw 19th Annual Global Investment Conference and Global Genes’ 2017 RARE Patient Advocacy Summit
September 05, 2017 08:00 ET
|
Fibrocell Science, Inc.
EXTON, Pa., Sept. 05, 2017 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ:FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective...
Fibrocell Reports Second Quarter 2017 Financial Results and Recent Highlights
August 09, 2017 08:00 ET
|
Fibrocell Science, Inc.
EXTON, Pa., Aug. 09, 2017 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ:FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue...
Fibrocell to Present at Canaccord Genuity 37th Annual Growth Conference
August 03, 2017 08:00 ET
|
Fibrocell Science, Inc.
EXTON, Pa., Aug. 03, 2017 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ:FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue...